Pharmacokinetic interaction: tibolone on dexamethasone

The term "Pharmacokinetic interaction: tibolone on dexamethasone" refers to the complex pharmacological interplay between the synthetic steroid tibolone and the glucocorticoid dexamethasone. Tibolone is a selective tissue estrogenic activity regulator (STEAR) used in hormone replacement therapy, which is metabolized into three active metabolites with estrogenic, progestogenic, and androgenic effects (PubChem, CID 35541). Dexamethasone is a potent agonist of the glucocorticoid receptor and a well-documented inducer of the hepatic enzyme Cytochrome P450 3A4 (CYP3A4) (StatPearls, Dexamethasone). Because tibolone and its metabolites are processed by hepatic enzymes, the induction of CYP3A4 by dexamethasone can lead to increased clearance and reduced plasma concentrations of tibolone, potentially compromising its therapeutic efficacy in treating menopausal symptoms (FDA, Dexamethasone Label). Conversely, while tibolone is not a strong inhibitor, its presence can theoretically compete for metabolic pathways shared by other steroids. Monitoring for reduced clinical response to tibolone is recommended when these drugs are used concomitantly. This interaction highlights the importance of considering enzyme induction profiles when managing patients on multi-steroid regimens.

Other names

Tibolone-dexamethasone interactionDexamethasone-tibolone interactionDrug-drug interaction between tibolone and dexamethasone

The interaction is primarily mediated by the induction of the Cytochrome P450 3A4 (CYP3A4) enzyme by dexamethasone, which increases the metabolic clearance of tibolone and its active metabolites (FDA, Dexamethasone Label; DrugBank, Tibolone).